Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab versus risankizumab for moderately to severely active Crohn's disease
NL-OMON61191Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in Crohn's disease comparing Guselkumab with Risankizumab (2 arms). Primary endpoint: Deep remission at Week 52. Started Jun 2026; status: recruiting.
02
Drugs
guselkumabrisankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON61191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61191.